All News

Several posters presented at the Heart Failure Society of America 2024 Annual Meeting looked into the landscape of guideline-directed medical therapy.

In posters presented at the Heart Failure Society of America 2024 Annual Meeting, researchers assessed how substance use disorders impact cardiovascular outcomes.

Among patients with heart failure, researchers aimed to understand the association between social detriments of health and physical frailty.

The once-daily, extended release, oral suspension medication was approved by the FDA in May 2024.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Lea Wolsoncroft of Remedies Pharmacy in Hoover, Alabama, discussed what is going on in her pharmacy practice.

Two posters presented at the Heart Failure Society of America 2024 Annual Meeting looked deeper into the topic of statin use in heart transplant recipients.

Researchers compared the cardiovascular outcomes of patients hospitalized for heart failure that did or did not experience diabetic emergencies.

Research presented at the Heart Failure Society of America 2024 Annual Meeting demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced cardiovascular events in patients without diabetes.

Angiotensin neprilysin inhibitors have shown to reduce the risk of death and hospitalization due to heat failure, but high prescription costs are a current barrier.

Left ventricular ejection fraction, brain natriuretic peptide, and heart failure-related hospitalizations were among the improved metrics.

Sara T. Thomason discuses the impact of stigma on pharmacists who are dealing with substance use disorder, the importance of mental health care, and how schools support pharmacy students dealing with addiction.

Investigators suggested that the future cost-effectiveness of respiratory syncytial virus (RSV) vaccination could be improved through lower vaccine prices and longer-lasting protection.

Researchers addressed the association between older individuals who received an influenza vaccine and their risk of stroke following vaccination.

Catch up on important pain management news from the month of September 2024.

In case you missed it, this week we had stories about pharmacists overcoming substance use disorder, the first new treatment approved for schizophrenia in decades, the Senate-Novo Nordisk hearing on semaglutide prices, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Check out these important FDA updates from the month of September 2024.

The National Foundation for Infectious Diseases released a survey regarding the feelings of US adults toward influenza, COVID-19, RSV, and pneumococcal disease.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the IL4 and IL13 pathways.

The approval of xanomeline and trospium chloride (Cobenfy) from Bristol Myers Squibb represents a “transformative moment in the treatment of schizophrenia.”

Without financial incentives, some senators expressed concerns that pharmaceutical research and development would stall.

Genentech said it’s sharing the data with global health authorities to make the therapy available to patients as soon as possible.

In the TEMPO-1 trial, both tavapadon doses effectively reduced motor symptoms in patients with early-stage Parkinson's disease.

Researchers aimed to address how community pharmacies target vulnerable groups regarding the promotion of vaccinations.

For National Recovery Month, Drug Topics sat down with Jake Nichols, PharmD, MBA, to discuss what kinds of resources there are for pharmacists dealing with a substance use disorder.

Study findings raise concern about increased pain and disability, poorer pain self-management, and impaired quality of life during adolescence that can continue into young adulthood.

Check out this list of our top 10 stories from September 2024.